Pharmacokinetics, absorption, and excretion of radiolabeled revexepride: a Phase I clinical trial using a microtracer and accelerator mass spectrometry-based approach

PURPOSE: Gastroesophageal reflux disease involves the reflux of gastric and/or duodenal content into the esophagus. Prokinetic therapies, such as the selective 5-hydroxytryptamine receptor 4 agonist revexepride, may aid gastric emptying. This Phase I study evaluated the pharmacokinetics and excretio...

Descripción completa

Detalles Bibliográficos
Autores principales: Flach, Stephen, Croft, Marie, Ding, Jie, Budhram, Ron, Pankratz, Todd, Pennick, Mike, Scarfe, Graeme, Troy, Steven, Getsy, Jay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045912/
https://www.ncbi.nlm.nih.gov/pubmed/27729771
http://dx.doi.org/10.2147/DDDT.S107843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045912/
https://www.ncbi.nlm.nih.gov/pubmed/27729771
http://dx.doi.org/10.2147/DDDT.S107843

Ejemplares similares